The maternal serological response to intrauterine Ureaplasma sp infection and prediction of risk of pre-term birth

被引:12
作者
Ireland, Demelza J. [1 ]
Keelan, Jeffrey A. [1 ]
机构
[1] Univ Western Australia, Sch Womens & Infants Hlth, Crawley, WA 6009, Australia
来源
FRONTIERS IN IMMUNOLOGY | 2014年 / 5卷
基金
英国医学研究理事会;
关键词
antibody; immune response; intrauterine infection; pre-term birth; predictive marker; Ureaplasma spp; LINKED-IMMUNOSORBENT-ASSAY; POLYMERASE-CHAIN-REACTION; MYCOPLASMA-HOMINIS; AMNIOTIC-FLUID; INTRAAMNIOTIC INFECTION; UREALYTICUM INFECTION; MICROBIAL INVASION; PREMATURE RUPTURE; PREGNANT-WOMEN; MB ANTIGEN;
D O I
10.3389/fimmu.2014.00624
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pre-term birth (PTB) associated with intrauterine infection and inflammation (IUI) is the major cause of early PTB less than 32 weeks of gestation. Ureaplasma spp. are common commensals of the urogenital tract in pregnancy and are the most commonly identified microorganisms in amniotic fluid of pre-term pregnancies. While we have an understanding of the causal relationship between intra-amniotic infection, inflammation and PTB, we are still unable to explain why vaginal Ureaplasma sp. colonization is tolerated in some women but causes PTB in others. It is now known that placental tissues are frequently colonized by bacteria even in apparently healthy pregnancies delivered at term; usually this occurs in the absence of a significant local inflammatory response. It appears, therefore, that the site, nature, and magnitude of the immune response to infiltrating microorganisms are key in determining pregnancy outcome. Some evidence exists that the maternal serological response to Ureaplasma sp. colonization may be predictive of adverse pregnancy outcome, although issues such as the importance of virulence factors (serovars) and the timing, magnitude, and functional consequences of the immune response await clarification. This mini-review discusses the evidence linking the maternal immune response to risk of PTB and the potential applications of maternal serological analysis for predicting obstetric outcome.
引用
收藏
页数:7
相关论文
共 79 条
[1]   The Placenta Harbors a Unique Microbiome [J].
Aagaard, Kjersti ;
Ma, Jun ;
Antony, Kathleen M. ;
Ganu, Radhika ;
Petrosino, Joseph ;
Versalovic, James .
SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (237)
[2]   Local inflammatory response in choriodecidua induced by Ureaplasma urealyticum [J].
Aaltonen, R. ;
Heikkinen, J. ;
Vahlberg, T. ;
Jensen, J. S. ;
Alanen, A. .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2007, 114 (11) :1432-1435
[3]  
Agbakoba N R, 2007, West Afr J Med, V26, P28
[4]  
Alfirevic Z., 2003, The Cochrane database of systematic reviews, pCD003252, DOI [10.1002/14651858, DOI 10.1002/14651858.CD003252, 10.1002/14651858.CD003252]
[5]   Mycobacterial lipopeptides elicit CD4+ CTLs in Mycobacterium tuberculosis-infected humans [J].
Bastian, Max ;
Braun, Tobias ;
Bruns, Heiko ;
Roellinghoff, Martin ;
Stenger, Steffen .
JOURNAL OF IMMUNOLOGY, 2008, 180 (05) :3436-3446
[6]   Serum killing of Ureaplasma parvum shows serovar-determined susceptibility for normal individuals and common variable immuno-deficiency patients [J].
Beeton, Michael L. ;
Daha, Mohamed R. ;
El-Shanawany, Tariq ;
Jolles, Stephen R. ;
Kotecha, Sailesh ;
Spiller, O. Brad .
IMMUNOBIOLOGY, 2012, 217 (02) :187-194
[7]   Association of abnormal vaginal flora and Ureaplasma species as risk factors for preterm birth: a cohort study [J].
Breugelmans, Maria ;
Vancutsem, Ellen ;
Naessens, Anne ;
Laubach, Monica ;
Foulon, Walter .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2010, 89 (02) :256-260
[8]   MEASUREMENT OF ANTIBODY TO UREAPLASMA-UREALYTICUM BY AN ENZYME-LINKED IMMUNOSORBENT-ASSAY AND DETECTION OF ANTIBODY-RESPONSES IN PATIENTS WITH NON-GONOCOCCAL URETHRITIS [J].
BROWN, MB ;
CASSELL, GH ;
TAYLORROBINSON, D ;
SHEPARD, MC .
JOURNAL OF CLINICAL MICROBIOLOGY, 1983, 17 (02) :288-295
[9]   Ureaplasma urealyticum, Mycoplasma hominis and adverse pregnancy outcomes [J].
Capoccia, Romina ;
Greub, Gilbert ;
Baud, David .
CURRENT OPINION IN INFECTIOUS DISEASES, 2013, 26 (03) :231-240
[10]  
CASSELL GH, 1988, LANCET, V2, P240